Mercier Patrick, Alves-Branco Francisco, Sapper Maria de Fatima, White Christopher Roger
Medical Department, Virbac (SA) Laboratories, 06511 Carros Cedex, France.
Am J Vet Res. 2003 Oct;64(10):1221-4. doi: 10.2460/ajvr.2003.64.1221.
To evaluate the safety of an orally administered ivermectin and praziquantel paste with regard to variables associated with clinical findings, parturition, lactation, maternal care, and neonate viability in pregnant mares.
40 pregnant mares.
Mares were randomly allocated into treatment (n = 20) and control (20) groups and administered a placebo or 3 times the therapeutic dosage of ivermectin (0.6 mg/kg) and praziquantel (4.5 mg/kg) at 14-day intervals until parturition. Physical examinations were performed on mares and their foals after parturition (on postpartum days 30, 60, and 90) to identify any drug-related effects. As an aid in assessing general health, hematologic and serum biochemical analyses were performed monthly on the mares.
In blood constituents, minor alterations that were not biologically important were observed. Reproductive performance was not affected by the unusual treatment duration or high dosage, although the drugs were administered during a crucial period of equine embryonic development (30 to 60 days). Neither adverse effects on mares nor abortions occurred. Follow-up evaluations of the foals for a 3-month period did not detect any abnormalities.
Administration of the ivermectin-praziquantel paste appears to be safe in pregnant mares and their foals.
评估口服伊维菌素和吡喹酮糊剂对妊娠母马临床检查、分娩、泌乳、母性行为及新生驹活力等相关变量的安全性。
40匹妊娠母马。
将母马随机分为治疗组（n = 20）和对照组（20匹），给予安慰剂或3倍治疗剂量的伊维菌素（0.6 mg/kg）和吡喹酮（4.5 mg/kg），每隔14天给药1次，直至分娩。分娩后（产后第30、60和90天）对母马及其驹进行体格检查，以确定是否存在任何药物相关影响。为辅助评估总体健康状况，每月对母马进行血液学和血清生化分析。
在血液成分方面，观察到一些生物学上无重要意义的微小变化。尽管药物是在马胚胎发育的关键时期（30至60天）给药，但生殖性能并未受到异常治疗时间或高剂量的影响。母马既未出现不良反应，也未发生流产。对驹进行为期3个月的随访评估未发现任何异常。
伊维菌素-吡喹酮糊剂对妊娠母马及其驹的给药似乎是安全的。
